Target General Infomation
Target ID
T03313
Former ID
TTDR01101
Target Name
Interleukin-2 receptor alpha chain
Gene Name
IL2RA
Synonyms
CD25 antigen; IL-2 receptor alpha subunit; P55; TAC antigen; IL2RA
Target Type
Successful
Disease Autoimmune diabetes [ICD10: E08-E13]
Chronic lymphocytic leukaemia [ICD10: C91]
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26]
Heart transplant rejection [ICD9: 996; ICD10: T86]
Hodgkin's lymphoma [ICD10: C81]
Organ transplant rejection [ICD9: 279.5, 996; ICD10: D89.8, T86]
Function
Receptor for interleukin-2.
BioChemical Class
Transmembrane protein
Target Validation
T03313
UniProt ID
Sequence
MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS
GSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS
LPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP
QLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ
VAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI
Drugs and Mode of Action
Drug(s) Basiliximab Drug Info Approved Organ transplant rejection [1], [2]
Inolimomab Drug Info Phase 3 Heart transplant rejection [3]
LMB-2 Drug Info Phase 2 Chronic lymphocytic leukaemia [4]
RFT-5.dgA Drug Info Phase 2 Human immunodeficiency virus infection [5]
CHT-25 Drug Info Phase 1 Hodgkin's lymphoma [6]
HuMax-TAC Drug Info Terminated Autoimmune diabetes [7]
Modulator Basiliximab Drug Info [8]
CHT-25 Drug Info [6]
Inolimomab Drug Info
LMB-2 Drug Info [4]
RFT-5.dgA Drug Info
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Measles
HTLV-I infection
NetPath Pathway IL5 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
TNFalpha Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL12-mediated signaling events
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Arf6 trafficking events
SHP2 signaling
IL2-mediated signaling events
IL2 signaling events mediated by PI3K
IL2 signaling events mediated by STAT5
Calcium signaling in the CD4+ TCR pathway
Downstream signaling in na&amp
#xef
ve CD8+ T cells
IL12 signaling mediated by STAT4
Reactome GPVI-mediated activation cascade
gamma signalling through PI3Kgamma
Interleukin-2 signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways IL-2 Signaling Pathway
Inflammatory Response Pathway
Interleukin-2 signaling
Allograft Rejection
TSLP Signaling Pathway
IL-7 Signaling Pathway
Interleukin-3, 5 and GM-CSF signaling
References
REF 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
REF 2(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6879).
REF 3New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
REF 4Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
REF 5ClinicalTrials.gov (NCT00667017) RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
REF 6A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
REF 7Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018175)
REF 8Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.